Lung Cancer Detection and Diagnosis in Babylon Governorate by Gender and Age Group

Abstract

Lung cancer is one of the global health problems that has a high incidence and mortality rate. Particularly, it is one cancer that comes under strong effect of age, sex and lifestyle. This study included lung cancer as Babylon Governorate in terms of age groups and sex of the study, and the most important risk factors and methods of diagnosis are seen. Abstract This study has cross sectional design, this study was done in some of the hospitals of Babylon Governorate. Results: The results of the present study showed that the study population consisted of 160 lung cancer patients (120 males, 40 females) with mean age of 62.3 years. The risk factors and clinical symptoms were examined after stratifying the cases according to age and sex. The results showed that the rate of lung cancer was higher in males than females and significantly increased with increasing age. Smoking was the most common risk factor followed by being around chemicals at work and pollution in the environment. The main symptoms found were persistent cough and respiratory problems and chest pain, which resulted in late-stage medical consultations. Diagnosis was accomplished using a combination of methods ranging from chest radiography to computed tomography (CT) imaging to tissue biopsies. The results of the study highlight the importance of detecting lung cancer early, especially among older people and smokers, due to the significant influence of this on the efficacy of the therapeutics and the reduction of adverse effects. Furthermore, the research calls for the improvement of health education programs and the adoption of wider screening programs to help reduce the impact of this disease on society.

Keywords:

lung cancer, Detection, Babylon Governate, Age group

References

W. Alberg et al., “Lung Cancer Epidemiology,” Chest, vol. 138, no. 1, pp. 971- 979, Jul. 2010.

R. L. Siegel et al., “Cancer Statistics, 2023,” CA Cancer J. Clin., vol. 73, no. 1, pp. 7-33, Jan. 2023.

World Health Organization, “Global Cancer Observatory: Lung Cancer,” WHO, Geneva, Switzerland, 2020.

D. Shapira and M. Cote, “Cancer Progress and Priorities: Lung Cancer,” Cancer Epidemiol. Biomarkers Prev., vol. 28, no. 10, pp. 1563-1579, Oct. 2019.

J. R. Molina et al., “Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship,” Mayo Clin. Proc., vol. 83, no. 5, pp. 584-594, May 2008.

R. S. Herbst et al., “Lung Cancer,” N. Engl. J. Med., vol. 359, no. 13, pp. 1367-1380, Sep. 2008.

R. Govindan et al., “Changing Epidemiology of Lung Cancer in the United States,” J. Clin. Oncol., vol. 24, no. 28, pp. 4539-4544, Oct. 2006.

J. Ferlay et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates,” Int. J. Cancer, vol. 149, no. 4, pp. 778-789, Aug. 2021.

P. A. Bunn, “Early Detection of Lung Cancer,” Clin. Cancer Res., vol. 21, no. 17, pp. 3736-3740, Sep. 2015.

National Cancer Institute, “Lung Cancer Treatment (PDQ®)–Health Professional Version,” NCI, Bethesda, MD, USA, 2022.

L. A. Torre et al., “Global Lung Cancer Statistics,” CA Cancer J. Clin., vol. 65, no. 2, pp. 87-108, Mar. 2015.

S. G. Spiro and G. A. Silvestri, “One Hundred Years of Lung Cancer,” Am. J. Respir. Crit. Care Med., vol. 172, no. 5, pp. 523-529, Sep. 2005.

A. Jemal et al., “Global Cancer Statistics,” CA Cancer J. Clin., vol. 61, no. 2, pp. 69-90, Mar. 2011.

K. Inamura, “Lung Cancer: Understanding Its Molecular Pathology,” Int. J. Clin. Oncol., vol. 23, no. 1, pp. 1-10, Feb. 2018.

F. Islami et al., “Tobacco Smoking and Lung Cancer,” Transl. Lung Cancer Res., vol. 6, no. 3, pp. 223-233, Jun. 2017.

C. S. Dela Cruz et al., “Lung Cancer: Epidemiology, Etiology, and Prevention,” Clin. Chest Med., vol. 32, no. 4, pp. 605-644, Dec. 2011.

American Cancer Society, “Lung Cancer Facts & Figures 2023,” ACS, Atlanta, GA, USA, 2023.

F. R. Hirsch et al., “Lung Cancer: Current Therapies and New Targeted Treatments,” Lancet, vol. 389, no. 10066, pp. 299-311, Jan. 2017.

R. Ettinger et al., “NCCN Guidelines for Non-Small Cell Lung Cancer,” National Comprehensive Cancer Network, 2023.

N. H. Hanna et al., “Therapeutic Advances in Lung Cancer,” J. Thorac. Oncol., vol. 15, no. 2, pp. 115-130, Feb. 2020.

M. Reck et al., “Immunotherapy in Lung Cancer,” Lancet Oncol., vol. 20, no. 1, pp. 123-134, Jan. 2019.

P. Goldstraw et al., “The IASLC Lung Cancer Staging Project: TNM Classification,” J. Thorac. Oncol., vol. 11, no. 1, pp. 39-51, Jan. 2016.

R. S. Herbst et al., “The Biology of Lung Cancer,” Nature, vol. 553, no. 7689, pp. 446-454, Jan. 2018.

M. Peters et al., “Lung Cancer Screening,” JAMA, vol. 325, no. 10, pp. 962-970, Mar. 2021.

International Agency for Research on Cancer, “Lung Cancer Risk Factors,” IARC Monographs, Lyon, France, 2020.